Financial Data and Key Metrics Changes - Maravai reported $244.3 million in revenue for Q1 2022, a 65% increase year-over-year and a 7% increase sequentially [7] - Adjusted EBITDA was $187 million, up 85% year-over-year, with a record adjusted EBITDA margin of 77% [7][35] - Adjusted earnings per share for the quarter was $0.54 [7][38] - The company ended the quarter with $431 million in cash and $543 million in long-term debt [39][42] Business Line Data and Key Metrics Changes - The nucleic acid production business generated record revenue of $223.7 million, an 80% increase year-over-year, with a 55% growth in the base nucleic acid business excluding COVID-19-related revenues [10][44] - The biologics safety testing business achieved revenue of $20.6 million, a 17% increase from the previous year, driven by demand for ELISA kits [23][49] Market Data and Key Metrics Changes - The company maintains a strong position in the nucleic acid production market, collaborating with 18 out of the 20 top R&D spenders in 2021 [19] - The demand for COVID-19 vaccines remains uncertain, but the company expects it to continue being a meaningful revenue contributor [15][18] Company Strategy and Development Direction - Maravai is focused on expanding its product portfolio and market leadership while investing in operations and innovation [18][58] - The integration of the MyChem acquisition is progressing well, enhancing capabilities in critical raw materials for various therapies [28][47] - The company plans to invest $65 million to $75 million in capacity expansion for new facilities [40][41] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the dynamic nature of the COVID-19 vaccine market and the variability in demand [13][15] - The company is optimistic about the growth of its base nucleic acid production business, expecting around 30% growth overall for the year [52] - The adjusted EBITDA guidance for 2022 has been increased to a range of $650 million to $690 million [53] Other Important Information - The company is actively pursuing inorganic growth opportunities and expects to announce additional acquisitions in 2022 [31][82] - The biologics safety testing business is expected to moderate growth but remains strong, with a focus on high-quality testing solutions [76] Q&A Session Summary Question: Commentary on COVID revenue and outlook for 2023 - Management indicated limited ability to provide firm commentary on 2023 due to market variability but feels confident about 2022 guidance [61][62] Question: Customer funnel and CleanCap agreements - Management noted an increase in customers seeking all-inclusive services beyond CleanCap, indicating a growing focus on comprehensive solutions [64][65] Question: Trends in GMP-grade demand - There is increasing concern from customers regarding product quality, leading to more investments in facilities to meet GMP standards [69][70] Question: Outlook for MyChem and revenue performance - MyChem's revenue was immaterial in Q1, but integration is progressing well, with expectations for future growth [86][87] Question: Margin outlook and differential from COVID and non-COVID CleanCap - The company expects overall margins to moderate in the second half of the year but remains optimistic about maintaining strong margins [88][90] Question: Structure of contracts with larger customers - Contracts with large customers are generally take-or-pay agreements, providing a high degree of coverage for future revenues [95][96]

Q1 2022 Financial Results (Nasdaq: MRVI) May 5, 2022 LifeSciences Today's Agenda Welcome Deb Hart, Head of Investor Relations 01 Financial Results & Guidance Kevin Herde, Chief Financial Officer 02 Business Highlights & Update Carl Hull, Chief Executive Officer 03 04 Q&A Session Carl Hull, Chief Executive Officer Kevin Herde, Chief Financial Officer 2 Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains, and our officers and representatives may from time-to-time make, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) | Delaware | 8731 | 85-2786970 | | --- | --- | --- | | (State o ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2021 Earnings Conference Call February 23, 2022 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Chief Executive Officer Kevin Herde - Executive Vice President and Chief Financial Officer Conference Call Participants Brandon Couillard - Jefferies Yuko Oku - Morgan Stanley Paul Knight - KeyBanc Capital Markets Matt Larew - William Blair Catherine Schulte - Baird Michael Ryskin - Bank of America Merrill Lynch John Sourbeer ...

Q4 2021 Financial Results (Nasdaq: MRVI) February 23, 2022 LifeSciences Today's Agenda Welcome Deb Hart, Head of Investor Relations 01 Financial Results & Guidance Kevin Herde, Chief Financial Officer 02 Business Highlights & Update Carl Hull, Chief Executive Officer 03 04 Q&A Session Carl Hull, Chief Executive Officer Kevin Herde, Chief Financial Officer 2 Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains, and our officers and representatives may from time-to-time ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...

Investor Presentation (Nasdaq: MRVI) November 2021 Sciences Forward looking statements and use of non-GAAP financial measures This presentation contains, and our officers and representatives may from time-to-time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this presentation which are not strictly historical statements constitute forward-looking statements, includin ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q3 2021 Results Conference Call November 10, 2021 5:00 PM ET Company Participants Debra Hart - Senior Director, IR Carl Hull - CEO Kevin Herde - EVP, CFO Conference Call Participants Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Dan Arias - Stifel John Sourbeer - UBS Paul Knight - KeyBanc Matt Larew - William Blair Michael Ryskin - Bank of America Catherine Schulte - Baird Operator Good day, and thank you for standing by. Welcome to the Q3 2021 Ma ...

Q2 2021 Financial Results (Nasdaq: MRVI) August 10, 2021 eSciences Today's Agenda Welcome Deb Hart, Head of Investor Relations 01 Financial Results & Guidance Kevin Herde, Chief Financial Officer 02 Business Highlights & Update Carl Hull, Chief Executive Officer 03 04 Q&A Session Carl Hull, Chief Executive Officer Kevin Herde, Chief Financial Officer 2 Forward looking statements and use of non-GAAP financial measures This presentation contains, and our officers and representatives may from time-to-time make ...